ATTR-CM Affects Women, Too

Why It Matters

Underrecognition of ATTR-CM in women leads to delayed treatment, worsening outcomes and perpetuates gender bias in cardiology research. Prompt diagnosis expands therapeutic benefit and informs more inclusive clinical guidelines.

Key Takeaways

• Women underrepresented in ATTR-CM research, skewing prevalence data
• Smaller heart size masks wall thickening, delaying diagnosis
• Symptoms in women often atypical, leading to misattribution
• Early FDA-approved therapies improve outcomes if started promptly
• Patient advocacy essential to trigger appropriate testing

Pulse Analysis

Transthyretin amyloid cardiomyopathy (ATTR‑CM) has traditionally been portrayed as a male‑dominant disease, with epidemiological surveys citing 70‑80 % of cases in men. This narrative stems from decades of cardiology trials that enrolled far fewer women, creating a feedback loop where clinicians expect the condition primarily in male patients. Recent commentary from Cleveland Clinic specialists underscores that the apparent gender gap is likely an artifact of under‑representation rather than true biology. As more women are screened, prevalence estimates are expected to rise, challenging long‑standing diagnostic algorithms.

The anatomical and clinical profile of women further obscures ATTR‑CM. Female hearts are generally smaller, so the hallmark ventricular wall thickening can fall below conventional imaging thresholds, leading radiologists to label findings as normal or attribute them to hypertension. Moreover, women often report atypical or milder fatigue, which is frequently dismissed as aging or anxiety. Recognizing ancillary clues—bilateral carpal tunnel syndrome, lumbar spinal stenosis, unexplained edema, or orthostatic hypotension—can prompt a targeted scintigraphy or biopsy, shortening the time to definitive diagnosis.

Three FDA‑approved agents now target the underlying transthyretin cascade, and clinical data show that initiating therapy before advanced heart failure dramatically improves survival and quality of life. Consequently, patient advocacy becomes a clinical imperative: women must voice their symptoms and request ATTR‑CM testing when red‑flag patterns emerge. Early detection not only benefits individual outcomes but also enriches trial enrollment, generating gender‑balanced evidence that can refine dosing, safety profiles, and long‑term management strategies. Bridging the diagnostic gap promises a more equitable cardiology landscape and better health economics for the aging population.